Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 633 participants.
Also called NCT06327815
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 633 participants
- Sponsor
- Registry
-
NCT06327815
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06327815. Randomized; no masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2025-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
- Intervention (Drug)
- Dapagliflozin tablets and Metformin HCl extended-release tablets
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06327815- Content hash
83919b89fba902b5847b4ab8ea6bcb330cfdc394327e99dd0e52d814aea6b217